Depression
Novartis/Servier drug expected to achieve blockbuster status in antidepressant market
Published in Drug Week, February 16th, 2007
The new Pharmacor report Outlook for Antidepressants, 2006-2016: Will Novel Agents Surprise the Market' finds that the melatonin agonist Valdoxan/Thymanax will experience rapid uptake as a first-line treatment in the primary care setting, following its launch in 2010. The report finds that, unlike other later-stage novel antidepressants, melatonin agonists do not have a history of tolerability issues and physicians have indicated acceptance of this class in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-02-16)
More Articles from Drug Week
- Cancer Therapy
MGI PHARMA reports publication of phase III data for Saforis Powder in UpTec - Market Analysis
Cutting Edge Information reports 42% of pharma firms outsource phase IV research - Alzheimer Disease Therapy
Saitama Medical University, Department of Pharmacology details research in Alzheimer disease therapy - Angiotensins
Research from Monash University has provided new information about angiotensins - Angiotensins
Research from University of Ioannina, Division of Cardiology has provided new information about angiotensins - Angiotensins
Research on angiotensins published by scientists at University of Texas - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
